Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Healthcare-associated infections: a threat to the survival of patients with COVID-19 in intensive care units

V. de Macedo a,b,c,*, G.S. Santos d, R.N. Silva e, C.N.M. Couto f, C. Bastos c, E. Viecelli c, M.N. Mateus c, M.E. Graf g, R.B. Gonçalves g, M.A. Silva g, P.D.B. Bernardini g, R.S.P. Grando g, V.P. Boaventura g, H.S.R. Pereira g, A.S.S. Levin c

a Hospital Infection Control and Epidemiology Center, Santa Casa de Curitiba, Curitiba, Paraná, Brazil
b Positive University, Medicine School, Curitiba, Paraná, Brazil
c Department of Infectious Diseases, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
d Hospital Infection Control and Epidemiology Center, Rehabilitation Hospital, Curitiba, Paraná, Brazil
e Infection Control Program, Hospital de Clínicas, Curitiba, Paraná, Brazil
f Pontifical Catholic University of Paraná, Medicine School, Curitiba, Paraná, Brazil
g Hospital Infection Control and Epidemiology Center, Trabalhador Hospital, Curitiba, Paraná, Brazil

ARTICLE INFO

Article history:
Received 23 March 2022
Accepted 17 May 2022
Available online 25 May 2022

Keywords:
COVID-19
Intensive care unit
Healthcare-associated infections
Risk factors
Fatality or mortality
Epidemiology

SUMMARY

Background: Wide variation in mortality rates among critically ill patients with coronavirus disease 2019 (COVID-19) has been reported. This study evaluated whether healthcare-associated infections (HAI) are a risk factor for death among patients with severe COVID-19 in the intensive care unit (ICU).

Methods: This retrospective cohort study included patients with severe COVID-19 hospitalized in the ICU of four hospitals in the city of Curitiba, Brazil. Patients with COVID-19 who died during ICU hospitalization were compared with those who were discharged. A second analysis compared patients who developed HAI in the ICU with those who did not. Multiple logistic regression models were used to control for confounders.

Results: In total, 400 patients were included, and 123 (31%) patients developed HAI. The most common HAI was lower respiratory tract infection (67%). Independent risk factors for death were: age [odds ratio (OR) 1.75, 95% confidence interval (CI) 1.43–2.15; P < 0.0001]; clinical severity score (OR 2.21, 95% CI 1.70–2.87; P < 0.0001); renal replacement therapy (OR 12.8, 95% CI 5.78–28.6; P < 0.0001); and HAI (OR 5.9, 95% CI 3.31–10.5; P < 0.0001). A longer interval between symptom onset and hospital admission was protective against death (OR 0.93, 95% CI 0.88–0.98; P = 0.017). The only independent factors associated with HAI were high C-reactive protein and low PaO2/FiO2 ratio.
**Introduction**

The link between viral outbreaks and secondary bacterial infections is well established, as observed during influenza and coronavirus pandemics [1,2]. However, healthcare-associated infections (HAI) have been described in patients with coronavirus disease 2019 (COVID-19) with highly variable incidence, ranging from 6.1% to 50.5% across studies, with most studies reporting incidence >15% [3–14].

Wide variation in mortality rates among critically ill patients with COVID-19 has been described, ranging from 15% to 75.9% [3,4,8,12–14], and reaching 97% among patients on invasive mechanical ventilation [15]. This variability has been explained by differences between cases and organizations, differences in ICU bed availability between countries, and different lengths of follow-up [12]. Few studies have assessed risk factors for mortality in critically ill patients with COVID-19. Independent risk factors include older age, male gender, low PaO2/FiO2 ratio at hospital admission, comorbidities and higher Sequential Organ Failure Assessment score [10,12,14]. Even fewer studies have explored how HAI influence the mortality rate of critically ill patients [3,4,9,13]. Studies merely present mortality data for patients with COVID-19 with HAI without assessing whether HAI is a prognostic factor and without analysing the predictive factors for HAI [5–7,9,11,12,14].

The objective of this study was to evaluate the risk factors for death and HAI for patients with COVID-19 in the critical care setting.

**Methods**

This retrospective cohort study included a cohort of adult patients (≥18 years) with severe COVID-19 hospitalized in the intensive care units (ICU) of four hospitals in Curitiba, capital of the state of Paraná, and largest city in Southern Brazil: Santa Casa with 249 beds (48 ICU beds); Trabalhador Hospital with 222 beds (40 ICU beds); Rehabilitation Hospital with 82 beds (62 ICU beds); and Institute of Medicine with 100 beds (60 ICU beds). The characteristics of the patients in each hospital are shown in Table S1 (see online supplementary material).

Consecutive patients with severe COVID-19, defined as those with oxygen saturation ≤94% on room air, or requiring supplemental oxygen, or requiring mechanical ventilation, or requiring extracorporeal membrane oxygenation [16], admitted to an ICU from 1st March to 31st December 2020 were included in the study. Recruitment was continued until there were 100 patients from each hospital.

COVID-19 was defined as an infection confirmed with a positive real-time reverse transcriptase polymerase chain reaction assay for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) from a nasopharyngeal swab. Patients with non-severe disease and those with COVID-19 defined by serological or antigen tests for SARS-COV-2 were excluded.

The following information was extracted from electronic medical records using a data collection form: demographic characteristics; clinical information (signs, symptoms, comorbidities); treatment and use of invasive devices in the ICU (otracheal tube, central venous catheter, indwelling urinary catheter); laboratory tests at ICU admission and at HAI diagnosis [C-reactive protein (CRP), total leukocyte count, number of lymphocytes, creatinine, glucose, D-dimer, troponin, PaO2/FiO2 ratio]; and radiologic alterations based on chest X ray or computed tomography scan. The interval from symptom onset to hospitalization, length of hospital stay and length of ICU stay were also documented.

The World Health Organization (WHO) Clinical Progression Scale [17] was used to measure the severity of illness for each patient at ICU admission: 0, not infected; 1–3, ambulatory mild disease; 4–5, hospitalized with moderate disease; 6–9, hospitalized with severe disease; and 10, dead.

HAI were defined according to Brazilian national surveillance criteria [18] that are based on Centers for Disease Control and Prevention criteria [19] (Table S2, see online supplementary material). Only the first infection for each patient was considered. Although the study was retrospective, diagnoses of HAI were obtained from data produced by a designated surveillance team in each hospital. Thus, diagnoses of HAI were produced in real time using standardized criteria.

Meticillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant enterococci (VRE), carbapenem-resistant (CR) Enterobacterales, CR *Acinetobacter* spp. and CR *Pseudomonas* spp. were defined as multi-drug-resistant (MDR) bacteria. This study was approved by the research ethics committees of the study hospitals (Protocol No. 4.361.502, CAAE: 382398 20.8.0000.5225).

**Data analysis**

The sample size was calculated using OpenEpi Version 3.01 [20] with the following parameters: confidence interval (CI) of 95%; statistical power of 80%; ratio of exposed and unexposed in the sample equal to 1.0; proportion of positive unexposed 5%; and odds ratio (OR) of 3. The sample size was calculated to be 400. Continuous variables were described using means, and categorical variables were described using frequency. Two outcomes in the ICU were studied (dependent variables): death and HAI. Both were followed until discharge from the ICU. Patients with COVID-19 who died during ICU hospitalization were compared with those who were discharged. A second analysis compared patients in the ICU who developed HAI with those who did not.

Possible associations of demographic and clinical variables with each dependent variable were initially tested in a bivariate analysis calculating OR and 95% CI for each variable. Variables potentially associated with the development of each dependent variable on bivariate analysis (P<0.15) were included in a multi-variate logistic regression model in order to

---

**Conclusions:** No factors that could point to a high-risk group for HAI acquisition were identified. However, age, dialysis and HAI increased the risk of death in ICU patients with severe COVID-19: of these, HAI is the only preventable risk factor.

© 2022 Published by Elsevier Ltd on behalf of The Healthcare Infection Society.
determine the adjusted OR. Age, CRP and PaO2/FiO2 ratio were transformed from continuous variables to categorical variables. For age, seven categories were used, according to Centers for Disease Control and Prevention criteria [21], to assess the risk of mortality for patients with COVID-19: 18–29 years, 30–39 years, 40–49 years, 50–64 years, 65–74 years, 75–84 years and ≥85 years. For CRP, the cut-off point was 108 mg/L, based on a study [22] which observed an increase in mortality

| Characteristics                          | Death | Survival | Bivariate analysis | P-value | Multi-variate analysis | P-value |
|------------------------------------------|-------|----------|--------------------|---------|------------------------|---------|
| **Age, years, mean (SD)**                | 67.4 (13.5) | 58.1 (15.6) | 0.02               | 1.75 (1.43–2.15) | 0.0001 |
| Gender, N (%)                            |       |          |                    |         |                        |         |
| Male                                     | 99 (52) | 125 (59) | 0.75 (0.50–1.12)   | 0.16    |                        |         |
| Female                                   | 90 (48) | 86 (41)  |                    |         |                        |         |
| Comorbidities, N (%)                     |       |          |                    |         |                        |         |
| Hypertension                             | 126 (67) | 108 (51) | 1.9 (1.2–2.8)      | 0.0018  |                        |         |
| Coronary heart disease                   | 58 (31) | 33 (16)  | 2.38 (1.4–3.8)     | 0.0004  |                        |         |
| Diabetes                                 | 67 (35) | 62 (29)  | 1.31 (0.86–2.0)    | 0.19    |                        |         |
| Chronic kidney disease                   | 12 (6) | 13 (6)   | 1.03 (0.45–2.3)    | 0.93    |                        |         |
| Chronic obstructive lung disease         | 22 (12) | 17 (8)   | 1.50 (0.77–2.9)    | 0.23    |                        |         |
| Cerebrovascular disease                  | 23 (12) | 14 (7)   | 1.94 (0.97–3.9)    | 0.06    |                        |         |
| Cancer                                   | 5 (3) | 2 (0.9)  | 2.83 (0.54–14)     | 0.21    |                        |         |
| **Body mass index, kg/m², N (%)**        |       |          |                    |         |                        |         |
| 18–24.9                                  | 16 (20) | 17 (14)  | 0.55 (0.24–1.2)    | 0.15    |                        |         |
| 25–29.9                                  | 27 (33) | 52 (41)  | 0.70 (0.31–1.5)    | 0.39    |                        |         |
| ≥30                                      | 38 (47) | 57 (45)  | 0.70 (0.31–1.5)    | 0.39    |                        |         |
| Signs and symptoms at hospital admission, N (%) |       |          |                    |         |                        |         |
| Cough                                    | 111 (59) | 156 (74) | 0.50 (0.32–0.76)   | 0.0014  |                        |         |
| Fever ≥37.8 °C                           | 83 (44) | 124 (59) | 0.54 (0.36–0.81)   | 0.0031  |                        |         |
| Dyspnoea                                 | 154 (81) | 177 (84) | 0.84 (0.50–1.4)    | 0.52    |                        |         |
| Desaturation (SpO2<92%)                  | 109 (51) | 124 (59) | 0.95 (0.64–1.4)    | 0.82    |                        |         |
| Fatigue                                  | 43 (23) | 70 (33)  | 0.59 (0.38–0.92)   | 0.02    |                        |         |
| Diarrhoea                                | 12 (6) | 12 (6)   | 1.12 (0.49–2.56)   | 0.78    |                        |         |
| Nausea or vomiting                       | 12 (6) | 24 (11)  | 0.52 (0.25–1.08)   | 0.08    |                        |         |
| Headache                                 | 11 (6) | 35 (17)  | 0.31 (0.15–0.63)   | 0.0012  |                        |         |
| Anosmia                                   | 20 (11) | 30 (14)  | 0.71 (0.39.1.3)    | 0.27    |                        |         |
| Dysgeusia                                | 15 (8) | 25 (12)  | 0.64 (0.32–1.2)    | 0.19    |                        |         |
| Sore throat                              | 5 (3) | 12 (6)   | 0.45 (0.15–1.3)    | 0.14    |                        |         |
| Treatment and device use in the ICU      |       |          |                    |         |                        |         |
| Pronation, N (%)                         | 117 (62) | 75 (35)  | 2.94 (1.9–4.4)     | <0.0001 | 12.8 (5.78–28.6)       | <0.0001 |
| Renal replacement therapy, N (%)         | 66 (35) | 11 (5)   | 9.7 (4.9–19)       | <0.0001 | 12.8 (5.78–28.6)       | <0.0001 |
| MV, N (%)                                | 181 (96) | 70 (33)  | 45.5 (21–97)       | <0.0001 |                        |         |
| Mean days of MV (SD)                     | 9 (6) | 10 (6)   | 0.09               |         |                        |         |
| CVC, N (%)                               | 177 (94) | 67 (32)  | 31.7 (16.5–60)     | <0.0001 |                        |         |
| Mean days of CVC (SD)                    | 8 (6) | 9 (4)    | 0.04               |         |                        |         |
| IUC, N (%)                               | 183 (97) | 87 (41)  | 43.3 (18–102)      | <0.0001 |                        |         |
| Mean days of IUC                         | 8 (6) | 8 (5)    | 1.00               |         |                        |         |
| Use of steroids, N (%)                   | 146 (77) | 134 (63) | 1.95 (1.2–3.0)     | 0.003   |                        |         |
| Use of anticoagulants, N (%)             | 185 (98) | 208 (99) | 0.66 (0.14–3.0)    | 0.59    |                        |         |
| Therapeutic dose                         | 19 (10) | 14 (7)   | 1.57 (0.76–3.23)   | 0.21    |                        |         |
| Prophylactic dose                        | 166 (90) | 194 (93) | 0.63 (0.32–1.2)    | 0.17    |                        |         |
| Use of antimicrobials, N (%)             | 182 (96) | 194 (9)  | 2.27 (0.92–5.6)    | 0.07    |                        |         |
| WHO scale score at ICU admission, mean (SD) | 5.9 (1.14) | 5.1 (0.82) | <0.0001 | 2.21 (1.70–2.87) | <0.0001 |
| Interval from symptom onset to ICU admission, days, mean (SD) | 6 (5) | 8 (4) | <0.0001 | 0.93 (0.88–0.98) | 0.017  |
| HAI in ICU, N (%)                        | 91 (48) | 33 (16)  | 5.0 (3.1–8.0)      | <0.0001 | 5.9 (3.31–10.5)        | <0.0001 |

CI, confidence interval; CVC, central venous catheter; HAI, healthcare-associated infections; ICU, intensive care unit; IUC, indwelling urinary catheter; MV, mechanical ventilation; OR, odds ratio; SD, standard deviation; SpO2, oxygen saturation; WHO, World Health Organization.
Table II
Bivariate analysis of factors potentially associated with acquiring healthcare-associated infections in patients admitted to intensive care units of four hospitals with severe coronavirus disease 2019 (Curitiba, Brazil; March–December 2020)

| Characteristics                              | HAI | Without HAI | OR (95% CI) | P-value |
|----------------------------------------------|-----|-------------|-------------|---------|
| Age, years, mean (SD)                        | 62.6 (13.7) | 62.4 (16) | 1.56 (1.01–2.41) | 0.90 |
| Gender, N (%)                                | 78 (63) | 146 (53) |  | 0.047 |
| Male                                         | 45 (37) | 131 (47) |  |  |
| Comorbidities, N (%)                         | 115 (94) | 259 (94) | 0.99 (0.42–2.36) | 0.99 |
| Hypertension                                 | 76 (61) | 158 (57) | 1.2 (0.78–1.88) | 0.37 |
| Coronary heart disease                       | 26 (21) | 64 (23) | 0.89 (0.53–1.49) | 0.66 |
| Diabetes                                     | 39 (32) | 89 (32) | 0.98 (0.62–1.55) | 0.93 |
| Chronic kidney disease                       | 7 (6) | 18 (6) | 0.87 (0.35–2.14) | 0.75 |
| Chronic obstructive lung disease             | 10 (8) | 29 (10) | 0.76 (0.36–1.61) | 0.46 |
| Cancer                                       | 2 (2) | 5 (2) | 0.89 (0.17–4.69) | 0.89 |
| Body mass index, kg/m², N (%)                | 7 (6) | 26 (9) | 2.3 (0.89–5.94) | 0.08 |
| 18–24.9                                      | 31 (25) | 50 (18) | 2.4 (0.93–6.0) | 0.06 |
| 25–29.9                                      | 37 (30) | 58 (21) |  |  |
| Signs and symptoms at hospital admission, N (%) | 78 (63) | 189 (68) | 0.80 (0.52–1.26) | 0.34 |
| Cough                                        | 108 (88) | 222 (80) | 1.78 (0.96–3.30) | 0.06 |
| Dyspnoea                                     | 67 (54) | 140 (50) | 1.17 (0.76–1.79) | 0.46 |
| Fever ≥37.8 °C                               | 77 (62) | 156 (56) | 1.30 (0.84–2.00) | 0.24 |
| Desaturation (SpO₂ <92%)                    | 43 (35) | 70 (25) | 1.59 (1.00–2.52) | 0.047 |
| Fatigue                                      | 4 (3) | 19 (7) | 0.45 (0.15–1.37) | 0.16 |
| Nausea or vomiting                           | 11 (9) | 25 (9) | 0.99 (0.47–2.08) | 0.97 |
| Headache                                     | 15 (12) | 31 (11) | 1.10 (0.57–2.12) | 0.77 |
| Anosmia                                      | 18 (15) | 31 (11) | 1.36 (0.73–2.54) | 0.33 |
| Dyseusia                                     | 11 (9) | 29 (10) | 0.84 (0.40–1.74) | 0.63 |
| Sore throat                                  | 4 (3) | 13 (5) | 0.68 (0.21–2.13) | 0.51 |
| Treatment and device use in the ICU          | 87 (71) | 106 (38) | 3.89 (2.46–6.16) | <0.0001 |
| Pronation, N (%)                             | 34 (28) | 43 (16) | 2.07 (1.24–3.46) | 0.0051 |
| Renal replacement therapy, N (%)             | 122 (98) | 129 (47) | 140 (19.3–1015) | <0.0001 |
| MV, N (%)                                    | 11 (7) | 7 (5) |  | <0.0001 |
| Mean days of MV (SD)                         | 119 (96) | 124 (45) | 36.7 (13.2–102) | <0.0001 |
| CVC, N (%)                                   | 10 (6) | 7 (5) |  | <0.0001 |
| Mean days of CVC (SD)                        | 121 (98) | 147 (53) | 53.5 (12.9–220) | <0.0001 |
| IUC, N (%)                                   | 10 (6) | 7 (5) |  | <0.0001 |
| Mean days of IUC (SD)                        | 96 (78) | 184 (66) | 1.79 (1.0–2.9) | 0.02 |
| Use of steroids, N (%)                       | 96 (78) | 177 (63) | 2.0 (1.2–3.2) | 0.0055 |
| Use of anticoagulants, N (%)                 | 11 (9) | 15 (5) | 1.71 (0.76–3.8) | 0.19 |
| Therapeutic dose                             | 85 (69) | 162 (58) | 1.58 (1.01–2.49) | 0.04 |
| Prophylactic dose                            | 121 (98) | 260 (94) | 2.6 (0.75–9.1) | 0.12 |
| Use of antimicrobials, N (%)                 | 108 (89) | 226 (87) | 1.6 (0.87–3.0) | 0.12 |
| Ceftriaxone                                  | 107 (88) | 223 (86) | 1.6 (0.88–2.9) | 0.11 |
| Azithromycin                                 | 26 (21) | 31 (12) | 2.1 (1.2–3.7) | 0.0097 |
| Piperacillin-tazobactam                      | 13 (11) | 16 (6) | 1.9 (0.89–4.1) | 0.09 |
| Amikacin                                     | 12 (10) | 15 (6) | 1.8 (0.85–4.1) | 0.11 |
| Meropenem                                    | 3 (2) | 4 (1) | 1.7 (0.37–7.7) | 0.48 |
| Levofoxacin                                  | 7 (6) | 1 (0.38) | 16 (2.0–136) | 0.0089 |
| Vancomycin                                   | 11 (9) | 9 (3.5) | 2.9 (1.1–7.2) | 0.02 |
| WHO scale score at ICU admission, mean (SD)  | 5.8 (1) | 5.5 (1) |  | 0.0059 |
| Interval between symptom onset and ICU       | 6.6 (4.9) | 7.1 (4.8) |  | 0.34 |
| admission, days, mean (SD)                   | 0.66 (1.2) | 0.61 (1.3) |  | 0.72 |

(continued on next page)
among patients with values above this cut-off. For PaO2/FiO2, four categories of severity for severe acute respiratory syndrome were used [23]: >300 mmHg, 200–299 mmHg, 100–199 mmHg and <100 mmHg.

Statistical analyses were performed using EPI-Info 7 Version 7.2.4 (Centers for Disease Control and Prevention, Atlanta, GA, USA). P<0.05 was considered to indicate statistical significance.

Results

Four hundred patients with severe COVID-19 hospitalized in ICUs were included in this study (100 patients from each hospital). Characteristics and outcomes of patients are shown in Tables I and II. Factors associated with increased risk of death on bivariate analysis were: older age; hypertension; coronary heart disease; presence of cough, fever, fatigue and headache at hospital admission; low leukocyte count, high CRP, low PaO2/FiO2 ratio, high troponin and high D-dimer on ICU admission; renal replacement therapy; and HAI. On multi-variate analysis, the variables that increased the risk of death significantly were: age; HAI; WHO Clinical Progression Scale score; and renal replacement therapy. A longer interval between symptom onset and hospital admission was protective against death. For each increase in age category, there was an increase in the risk of death by 75%. HAI increased the risk of death six-fold (OR 5.9, 95% CI 3.31–10.5; P<0.0001). Clinical severity according to the WHO scale increased the risk of death two-fold per point, and undergoing renal replacement therapy increased the risk of death 13-fold (Table I).

Among 400 patients studied, 123 had HAI (Table II); however, of these, 16 patients had two infections at the first diagnosis, so the total was 139 infections. The most common HAI were lower respiratory tract infections [68 (49%) ventilator-associated pneumonia (VAP), 17 (12%) tracheobronchitis, eight (6%) non-ventilator-associated pneumonia], followed by central-venous-catheter-related bloodstream infections [CLABSIs; 38 (27%)], catheter-associated urinary tract infections [CAUTIs; 7 (5%)], and tracheostomy stoma infection [1 (0.7%)]. The VAP rate was 29.3 per 1000 ventilator-days, the CLABSIs rate was 18.0 per 1000 catheter-days, and the CAUTI rate was 3.2 per 1000 catheter-days.

More than one-fifth of HAI were caused by MDR bacteria: CR Acinetobacter baumannii, CR Enterobacterales, MRSA, CR Pseudomonas spp. and VRE (Table III).

On bivariate analysis for factors associated with HAI, there was a significant difference in the mean number of days of use of invasive devices. WHO Clinical Progression Scale, CRP and PaO2/FiO2 values at ICU admission were higher in the HAI group. On multi-variate analysis, CRP >108 mg/L increased the risk of HAI 2-fold (OR 2.02, 95% CI 1.17–3.47; P<0.010). The PaO2/FiO2 ratio increased the chance of having HAI by 29% for each category (OR 1.29, 95% CI 1.01–1.66; P<0.04).

Discussion

This retrospective cohort study of 400 patients with COVID-19 admitted to the ICUs of four hospitals found that the independent factors associated with death were age, clinical severity score on ICU admission, dialysis and HAI. The interval between symptom onset and hospitalization was inversely associated with the risk of death. No factors that could point to a high-risk group for HAI acquisition were identified.

As HAI is the only modifiable factor associated with death, the authors attempted to identify independent factors associated with HAI. Is it possible to identify which patients are at higher risk of death, and therefore implement preventive measures directed at this population? Only CRP and PaO2/FiO2 ratio were found to be associated with HAI. Unfortunately, the changes in CRP and PaO2/FiO2 ratio may represent the consequence and not the cause or risk factors for HAI. Due to the severity of illness, these patients require mechanical
ventilation and invasive devices for prolonged periods, and are therefore more susceptible to HAI, especially lower respiratory tract infections [6].

Length of ICU stay, use of invasive devices, age, comorbidities and symptoms were not found to be predictive of which patients would develop HAI. It does not seem possible to identify which patients are at increased risk for HAI, which in turn increases the risk of death 6-fold. This risk was close to that found by Shafran et al. [13], who reported that one infection increased the risk of death 2.48-fold, and having more than one infection increased the risk of death 7.64-fold in patients with COVID-19.

It is important to stress that a large proportion of HAI caused by MDR bacteria such as CR *Acinetobacter baumannii* are preventable by implementing effective infection prevention control measures. In this study, 123 patients had 139 HAI, of which 29.1% (37/127 isolates) were caused by MDR bacteria. One of the possible explanations could be the extensive use of antimicrobials, especially at the beginning of the pandemic, when the clinical course of COVID-19 was not yet clear and there was a shortage of diagnostic tools [24]. In addition, in many countries, including Brazil, the heavy strain placed on the healthcare system by COVID-19 led to high demand for healthcare workers, and shortages of specialized and experienced personnel in hospitals with inadequate infrastructure, contributing to cross-transmission of pathogens between patients and MDR bacteria outbreaks.

Dialysis was associated with death in this study. The same mechanisms underlying the development of severe acute respiratory syndrome in COVID-19 appear to lead to acute kidney injury, including viral septicemia, an enhanced inflammatory response and endothelial damage [25].

The strengths of this study include the large number of patients and the multi-centre design. However, the study is limited by its retrospective design, which reduces control over multiple confounders and data collection. Also, only the first episode of infection was included in this study, which may have led to underestimation of the true burden of HAI. Furthermore, although this was a multi-centre study, only hospitals in Curitiba (Southern Brazil) were included, which may not reflect the reality of other geographical regions of Brazil. Finally, these hospitals could have had some differences in patterns of care and resources, which could be associated with the two outcomes of interest.

In conclusion, this study found that age, dialysis and HAI increased the risk of death among patients with severe COVID-19 in ICUs. PaO₂/FiO₂ and CRP were associated with HAI, but seem to be a consequence of the infection. No important factors that could define a population at increased risk for HAI were identified. As a consequence, infection prevention and control measures should be prioritized in order to reduce the impact of COVID-19 in critically ill patients.

**Table III**

Micro-organisms that caused healthcare-associated infections in patients with severe coronavirus disease 2019 admitted to the intensive care units of four hospitals (Curitiba, Brazil; March—December 2020)

| Type of infection                  | N (%) | MDR isolates          | N (%) |
|-----------------------------------|-------|-----------------------|-------|
| Microbiologically confirmed LRI  | 82 (65)| MRSA                  | 31 (84)|
| *Staphylococcus aureus*           | 22 (27)|                        | 7 (23) |
| *Acinetobacter baumannii*         | 17 (21)| CR *Acinetobacter baumannii* | 17 (55)|
| *Pseudomonas aeruginosa*          | 15 (18)| CR *Pseudomonas aeruginosa* | 3 (10)|
| *Klebsiella pneumoniae*           | 10 (12)| CR *Klebsiella pneumoniae* | 3 (10)|
| *Enterobacter cloacae*            | 5 (6) |                        | -     |
| *Stenotrophomonas maltophilia*    | 4 (5) |                        | -     |
| *Escherichia coli*                | 2 (2) | CR *Escherichia coli*   | 1 (3) |
| Others                            | 7 (9) |                        | -     |
| Bloodstream infections            | 38 (30)|                        | 6 (16) |
| Coagulase-negative staphylococci  | 12 (32)|                        | -     |
| *Enterococcus faecalis*           | 11 (29)| VRE                   | 1 (2) |
| *Staphylococcus aureus*           | 6 (16)| MRSA                 | 1 (2) |
| *Klebsiella pneumonia*            | 3 (8) |                        | -     |
| *Acinetobacter baumannii*         | 2 (5) | CR *Acinetobacter baumannii* | 2 (3) |
| *Serratia marcescens*             | 2 (5) | CR *Serratia marcescens* | 2 (3) |
| *Candida albicans*                | 2 (5) |                        | -     |
| Urinary tract infections          | 7 (6) |                        | -     |
| *Enterococcus faecalis*           | 4 (57)|                        | -     |
| *Klebsiella pneumonia*            | 2 (29)|                        | -     |
| *Enterobacter cloacae*            | 1 (14)|                        | -     |

CR, carbapenem-resistant; LRI, lower respiratory infection; MDR, multi-drug-resistant bacteria; MRSA, meticillin-resistant *Staphylococcus aureus*; VRE, vancomycin-resistant enterococci.

CR, carbapenem-resistant; LRI, lower respiratory infection; MDR, multi-drug-resistant bacteria; MRSA, meticillin-resistant *Staphylococcus aureus*; VRE, vancomycin-resistant enterococci.

In Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jhin.2022.05.013.

**Conflict of interest statement**

None declared.

**Funding sources**

None.
References

[1] Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008;198:962–70.

[2] Westblade LF, Simon MS, Satlin MJ. Bacterial coinfections in coronavirus disease 2019. Trends Microbiol 2021;29:930–41.

[3] Bardi T, Pintado V, Gomez-Rojo M, Escudero-Sanchez R, Lopez AA, Diez-Remesal Y, et al. Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. Eur J Clin Microbiol Infect Dis 2021;40:495–502.

[4] He Y, Li W, Wang Z, Chen H, Tian L, Liu D. Nosocomial infection among patients with COVID-19: a retrospective data analysis of 918 cases from a single center in Wuhan, China. Infect Control Hosp Epidemiol 2020;41:982–3.

[5] Li J, Wang J, Yang Y, Cai P, Caio J, Cai X, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrob Resist Infect Control 2020 22;9:153.

[6] Rouzé A, Martin-Löeches I, Povoa P, Makris D, Artigas A, Bouchereau M, et al. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Med 2021;47:188–98.

[7] Dudoignon E, Camélona F, Deniau B, Habay A, Coutrot M, Ressaire Q, et al. Bacterial pneumonia in COVID-19: the need for combination therapy with non-anti-SARS-CoV-2 agents? J Microbiol Immunol Infect 2020;53:505–12.

[8] Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med 2020;180:1345–55. Erratum in: JAMA Intern Med 2021;181:1021.

[9] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019-novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.

[10] Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect 2020;26:1395–9.

[11] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.

[12] Lai CC, Wang CY, Hsueh PR. Co-infections among patients with COVID-19: the need for combination therapy with non-anti-SARS-CoV-2 agents? J Microbiol Immunol Infect 2020;53:505–12.

[13] Shafran N, Shafran I, Ben-Zvi H, Sofer S, Sheena L, Krause I, et al. Secondary bacterial infection in COVID-19 patients is a stronger predictor for death compared to influenza patients. Sci Rep 2021;11:12703.

[14] Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med 2020;180:1436–47.

[15] Wang Y, Lu X, Li Y, Chen H, Chen T, Su N, et al. Clinical course and outcomes of 344 intensive care patients with COVID-19. Am J Respir Crit Care Med 2020;201:1430–4.

[16] US Food and Drug Administration. Remdesivir letter of EUA. Silver Spring, MD: FDA. Available at: https://www.fda.gov/media/137564/download [last accessed May 2020].

[17] WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 2020;20:e192–7.

[18] Brasil. Agência Nacional de Vigilância Sanitária. Critérios diagnósticos de infeções relacionadas à assistência à saúde. Agência Nacional de Vigilância Sanitária. Brasília: Anvisa; 2017.

[19] Centers for Disease Control and Prevention/National Healthcare Safety Network. CDC/NHSN surveillance definitions for specific types of infections. Atlanta, GA: CDC; 2020. Available at: https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnsindef_current.pdf [last accessed May 2022].

[20] Rawson TM, Ming D, Ahmad R, Moore LSP, Holmes AH. Antimicrobial use, drug-resistant infections and COVID-19. Nat Rev Microbiol 2020;18:409–10.

[21] Bruchfeld A. The COVID-19 pandemic: consequences for nephrology. Nat Rev Nephrol 2021;17:81–2.